CN104887668A - Application of Daphmalenine A derivate in antibacterial agent preparation - Google Patents
Application of Daphmalenine A derivate in antibacterial agent preparation Download PDFInfo
- Publication number
- CN104887668A CN104887668A CN201510240655.0A CN201510240655A CN104887668A CN 104887668 A CN104887668 A CN 104887668A CN 201510240655 A CN201510240655 A CN 201510240655A CN 104887668 A CN104887668 A CN 104887668A
- Authority
- CN
- China
- Prior art keywords
- daphmalenine
- application
- derivant
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *CCN1CCCCC1 Chemical compound *CCN1CCCCC1 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention relates to the field of organic synthesis and medicinal chemistry, in particular to a Daphmalenine A derivate, a Daphmalenine A derivate preparation method and an application of the Daphmalenine A derivate in antibacterial agent preparation. The novel Daphmalenine A derivate is synthesized, and the preparation method of the Daphmalenine A derivate is disclosed. Pharmacological experiments show that the Daphmalenine A derivate has an antibacterial effect and has value on the aspect of developing antibacterial agents.
Description
Technical field
The present invention relates to organic synthesis and medicinal chemistry art, be specifically related to Daphmalenine A derivant, preparation method and its usage.
Background technology
The health and lives of the mankind in the diffusion of pathogenic bacterium and the enhancing serious threat of drug resistance thereof, antibacterials are widely used in acquired immune deficiency syndrome (AIDS) as routine administration, organ transplantation and Chronic consumptions are (as cancer, diabetes, uremia etc.) treatment, although the antimicrobial agent used clinically is at present (as ketoconazole, amikacin, gentamycin, voriconazole, itraconazole, terbinafine, amphotericin, fluconazol etc.) better to the curative effect of skin and superficial place infection, but the cumulative toxicity of these antibacterials is stronger, usually cause lesions of liver and kidney, digestive tract stimulates, dizzy, irritated etc., so the novel antibacterial medicine finding mechanism of action uniqueness becomes one of focus of current medicament research and development.
Helicobacter pylori (Helicobacter pylori, Hp) is a kind of Gram-negative spiral bacteria.Research display, helicobacter pylori is the primary pathogenic event of acute and chronic gastritis and taste-blindness rate, and may fall ill relevant with gastric cancer stomach function regulating mucosa-associated lymphoid tissue (MALT) malignant lymphoma.Recently, Hp is classified as I class carcinogen by World Health Organization (WHO), and it plays a leading role in stomach cancer development.Simultaneously the scheme that popular at present treatment Hp infects takes the triple therapy that proton pump inhibitor (PPI) adds two kinds of antibiotic (clarithromycin, amoxicillin, tetracycline, metronidazole etc. select two kinds).The main factor affecting triple therapy is considered to the drug resistance of Hp to antibacterial; Another serious problems are that proton pump inhibitor can bring out dyspepsia, and a large amount of antibacterial then causes the serious destruction of flora in digestive tract.Therefore, find the active kind new medicine thing of efficient, safe anti-Hp and become an important and urgent task.
Global morbidity lungy is in increasing trend in recent years, estimate according to World Health Organization (WHO) (WHO), the current whole world is by mycobacterium tuberculosis (Mycobacterium tuberculosis, MTB) population infected accounts for 1/3rd of world population, and wherein the infected of 5 ~ 10% becomes tuberculosis patient.There is active tuberculosis patient 1,300,000 example in China, wherein infectiousness pulmonary tuberculosis about 600,000 example every year, wherein infectiousness pulmonary tuberculosis about 600,000 example, is one of global tuberculosis high burden country.
Come out one after another from antituberculotics, make treatment lungy play epoch-making change.But due to the Case management still not very specification of tuberculosis patient, irregular chemotherapy, abuse antituberculotics, makes drug resistance of tuberculosis situation day by day serious, and the change of drug resistance more trends towards multi-medicament drug resistance simultaneously, this causes extreme difficulties to preventing and controlling lungy.Therefore find new antituberculotics, the antituberculotics of especially anti-multidrug resistance is to protection people's health, significant.
From natural product, find compound or lead compound and carry out structural modification and obtain its derivant, thus the potential drug obtaining high-efficiency low-toxicity there is important value most.
The Compound D aphmalenine A that the present invention relates to is one and within 2011, delivers (Yu Zhang et al., 2011.Daphmalenines A and B:Two New Alkaloids with Unusual Skeletons from Daphniphyllum himalense.Eur.J.Org.Chem.2011,4103 – 4107) compound, we have carried out structural modification to Compound D aphmalenine A, obtain a new Daphmalenine A derivant, and its antibacterial activity is evaluated, it has antibacterial activity.
Summary of the invention
The invention discloses a Daphmalenine A derivant, its structure is:
Daphmalenine A derivant (III) of the present invention is by method preparation below:
(1) Daphmalenine A (I) and glycol dibromide are obtained by reacting the O-bromoethyl derivant (II) of Daphmalenine A;
(2) O-bromoethyl derivant (II) and the pyrrolidine generation substitution reaction of Daphmalenine A obtain O-(nafoxidine base) ethyl derivative (III) of Daphmalenine A.
The preparation method of the O-(nafoxidine base) ethyl derivative (III) of further Daphmalenine A is:
(1) 419mg Compound D aphmalenine A (I) is dissolved in 10mL benzene, in solution, adds the tetrabutyl ammonium bromide of 0.08g, the glycol dibromide of 7.520g and 50% sodium hydroxide solution of 6mL; Mixture stirs 12h at 35 degrees Celsius; After 12h, reactant liquor is poured in frozen water, use dichloromethane extraction twice immediately, merge organic phase solution; Then use water and saturated common salt water washing 4 times successively to organic phase solution, then use anhydrous sodium sulfate drying, last concentrating under reduced pressure is removed solvent and is obtained product crude product; Product crude product purification by silica gel column chromatography, mobile phase is: petroleum ether/acetone=100:1.5, v/v, collects the yellow yellow solid concentrating elution band namely to obtain the O-bromoethyl derivant (II) of Daphmalenine A.
(2) the O-bromoethyl derivant (II) of the Daphmalenine A of 263mg is dissolved in the middle of 20mL acetonitrile, adds the Anhydrous potassium carbonate of 345mg wherein, the potassium iodide of 84mg and the pyrrolidine of 2840mg, mixture reflux 12h; After reaction terminates, reactant liquor is poured in 20mL frozen water, with equivalent dichloromethane extraction four times, merge organic facies; Organic facies after merging with water and saturated common salt water washing successively, then use anhydrous sodium sulfate drying, concentrating under reduced pressure is removed solvent and is obtained product crude product; Product crude product purification by silica gel column chromatography, mobile phase is: petroleum ether/acetone=100:1.5, v/v, collects the brown gummy solid 183.2mg that namely brown concentrated elution band obtains the O-(nafoxidine base) ethyl derivative (III) of Daphmalenine A.
Compound disclosed by the invention can make pharmaceutically acceptable salt or pharmaceutically acceptable carrier.
Pharmacodynamic experiment shows, Daphmalenine A derivant (III) of the present invention has good antibacterial action.Pharmaceutically acceptable salt of the present invention has same drug effect with its compound.
Further, the experiment in vitro of compound III shows, chemicals III has very strong human body fungi activity, and therefore chemicals III of the present invention is expected to be used to prepare novel anti-human fungi medicine.
Further, the experiment in vitro of compound III shows, compound III has very strong anti Helicobacter pylori activity, illustrate for the diseases such as the closely-related acute and chronic gastritis of helicobacter pylori, duodenal ulcer, compound III is the compound of a great exploitation potential for its.It can be directly used in the treatment of corresponding disease and the preparation of related drugs.
Further, the experiment in vitro of compound III shows, compound III has the effect of very strong suppression escherichia coli, fluorescent pseudomonas, Staphylococcus aureus, Bacillus proteus, neogenesis cryptococcus, so compound III can be used as the compound with antibacterial actions, and be expected to be applied preparing in anti-bacterial drug.
Further, according to the result of preliminary test, the present invention with solid medium By Dilution this compound to the minimal inhibitory concentration of bacillus calmette-guerin vaccine, the H37Rv strain of mycobacterium tuberculosis type strain and substance of medicines-resistant branched tubercle bacillus (MDR MTB) three kinds of tulases, experimental result confirms that compound III has very strong anti-tubercle bacillus and anti-drug resistance tulase is active, can be used as the lead compound for the treatment of tubercle bacillus affection disease, also can be used for preparation treatment tubercular drugs.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Detailed description of the invention
The preparation of embodiment 1 Compound D aphmalenine A
Document (the Yu Zhang et al. that the people such as the preparation method reference Yu Zhang of Compound D aphmalenine A (I) deliver, 2011.Daphmalenines A and B:Two New Alkaloids with Unusual Skeletons from Daphniphyllum himalense.Eur.J.Org.Chem.2011,4103 – 4107) method.
The synthesis of the O-bromoethyl derivant (II) of embodiment 2Daphmalenine A
By Compound I (419mg, 1.00mmol) be dissolved in 10mL benzene, add in solution tetrabutyl ammonium bromide (TBAB) (0.08g), 1,50% sodium hydroxide solution of 2-Bromofume (7.520g, 40.00mmol) and 6mL.Mixture stirs 12h at 35 degrees Celsius.After 12h, reactant liquor is poured in frozen water, use dichloromethane extraction twice immediately, merge organic phase solution.Then use water and saturated common salt water washing 4 times successively to organic phase solution, then use anhydrous sodium sulfate drying, last concentrating under reduced pressure is removed solvent and is obtained product crude product.Product crude product purification by silica gel column chromatography (mobile phase is: petroleum ether/acetone=100:1.5, v/v), collects the yellow yellow solid (320mg, 61%) concentrating elution band namely to obtain Compound II per.
1H NMR(500MHz,DMSO-d
6)δ3.84(d,J＝1.6Hz,2H),3.76–3.50(m,5H),3.42(s,2H),3.09(s,1H),2.99(s,1H),2.88(s,1H),2.70(s,1H),2.64(d,J＝19.1Hz,3H),2.45(d,J＝5.6Hz,3H),2.33(s,1H),2.19–2.12(m,5H),2.07(s,1H),1.97(d,J＝9.2Hz,3H),1.84–1.76(m,3H),1.69(s,1H),1.15(s,1H),1.04(s,3H)。
13C NMR(125MHz,DMSO-d6)δ219.71(s),211.07(s),176.65(s),66.24(s),65.38(s),63.59(s),59.42(s),54.79(s),52.18(s),46.22(s),46.01(s),45.50(s),45.27(s),40.33(s),37.86(s),37.61(s),36.27(s),34.26(s),30.89(s),28.52(s),26.04(s),25.24(s),8.50(s)。
HRMS(ESI)m/z[M+H]
+calcd for C
25H
37BrNO
6:526.1804；found 526.1801.
The synthesis of the O-(nafoxidine base) ethyl derivative (III) of embodiment 3Daphmalenine A
Compound II per (263mg, 0.5mmol) is dissolved in the middle of 20mL acetonitrile, adds Anhydrous potassium carbonate (345mg wherein, 2.5mmol), potassium iodide (84mg, 0.5mmol) and pyrrolidine (2840mg, 40mmol), mixture reflux 12h.After reaction terminates, reactant liquor is poured in frozen water, with equivalent dichloromethane extraction four times, merge organic facies.Organic facies after merging with water and saturated common salt water washing successively, then use anhydrous sodium sulfate drying, concentrating under reduced pressure is removed solvent and is obtained product crude product.(mobile phase is product crude product purification by silica gel column chromatography: petroleum ether/acetone=100:1.5, v/v), collect the brown gummy solid (183.2mg, 71%) that namely brown concentrated elution band obtains the O-(nafoxidine base) ethyl derivative (III) of Daphmalenine A.
1H NMR(500MHz,DMSO-d6)δ3.80(s,1H),3.71(s,3H),3.50(s,2H),3.14(s,1H),3.06(s,1H),2.86(s,1H),2.73(d,J＝2.7Hz,2H),2.67(d,J＝5.3Hz,4H),2.55(s,4H),2.53–2.36(m,4H),2.21–2.15(m,5H),2.16–1.86(m,4H),1.85(d,J＝7.5Hz,2H),1.78(s,1H),1.72(d,J＝10.7Hz,5H),1.14(s,1H),1.08(s,3H)。
13C NMR(125MHz,DMSO-d6)δ219.76(s),211.10(s),176.66(s),66.23(s),63.55(s),61.51(s),59.41(s),54.83(s),54.50(s),53.87(s),52.18(s),46.20(s),46.04(s),45.53(s),45.24(s),40.32(s),37.87(s),37.64(s),36.26(s),30.85(s),28.50(s),25.95(s),25.18(d,J＝8.8Hz),8.42(s)。
HRMS(ESI):m/z[M+H]
+calcd for C
29H
45N
2O
6:517.3278；found:517.3271。
The preparation of embodiment 4 Compound II per involved in the present invention and III tablet
Get the one in the middle of 20 g of compound II or III or its pharmaceutically acceptable salt, add the customary adjuvant 180 grams preparing tablet, mixing, conventional tablet presses makes 1000.
The preparation of embodiment 5 Compound II per involved in the present invention and III capsule:
Get the one in the middle of 20 g of compound II or III or its pharmaceutically acceptable salt, add prepare capsule customary adjuvant as starch 180 grams, mixing, encapsulatedly makes 1000.
O-(nafoxidine base) ethyl derivative (III) the human body fungi activity of embodiment 6Daphmalenine A
1-ethyl pyrrolidine (compound IV) is commercially available analytical pure.
The experiment of human body fungi activity is the method adopting concentration dilution, and in triplicate, the pathogen of test has trichophyton, microsporum canis and trichophyton tonsurans to each mensuration, and bacterial concentration is 10
5individual/mL.The initial concentration of medicine is 50.00 μ g/mL (5% dimethyl sulfoxide DMSO), gradient dilution to 0.10 μ g/mL, the bacterium liquid of equivalent volumes and test sample Mixed culture (ultimate density of formation has: 25.00,12.50,6.25,3.13,1.56,0.78,0.39,0.20,0.10 and 0.05 μ g/mL) in 96 orifice plates, Human Fungi cultivation temperature is respectively 28 DEG C, observe after incubation time 24h, if find, in the disposal hole not having bacterium colony to be formed, that minimum concentration is sample lowest concentration of antimicrobial, i.e. MIC value.This experiment positive control is ketoconazole, and chemicals III human body fungus the results are shown in Table 1.
Table 1 chemicals III human body fungus MIC value (μ g/mL)
Conclusion: chemicals III has very strong human body fungi activity, therefore chemicals III of the present invention is expected to be used to prepare novel anti-human fungi medicine.Chemicals I and 1-ethyl pyrrolidine nonreactive Human Fungi activity, therefore can not for the preparation of novel anti-human fungi medicine.
Embodiment 7 compound III anti-helicobactor pylori activity
1) strains tested
Helicobacter pylori (Helicobacter pylori, Hp) reference culture ATCC 43504 is purchased from U.S.'s Culture Collection (American Type Culture Collection, ATCC).13 strain Hp clinical strains are picked up from Nanjing drum tower hospital Dndoscope Laboratory and are accepted gastroscopic patient; To the patient of peptic ulcer, duodenal bulbar inflammation or gastritis verrucosa in continuous gastroscopy, first be defined as Hp positive through RUT experiment, get antral gastric mucosa 1-2 block again, be inoculated in containing 8% horse serum, trimethoprim (trimethropin after chopping, in the Columbia selectivity agar culture medium of TMP) 1.25g/L, polymyxin (polymyxin) B2500U/L, vancomycin (vancomycin) 10mg/L, in 37 DEG C of (5%O under micro-oxygen environment
2, 10%CO
2and 85%N
2) cultivate 72 hours.Collect antibacterial, through smear Gram’s staining, after oxidase, catalase and urease are accredited as the positive, pure culture of going down to posterity, obtained strains is as experimental strain.
2) strain culturing
We adopt micro-aerobic bag (purchased from Shanghai Medical Univ) to carry out the strain culturing of HP, and it produces the micro-aerobic environment required for Hp by chemical reaction.
3) biological activity determination
Paper disk method (Microbiological paper method) is adopted to measure the inhibitory action of compound to helicobacter pylori, the minimum inhibitory concentration (minimal inhibitory concentration, MIC) of test sample is measured with agar dilution.
I. paper disk method experiment
(A) culture medium is prepared by the Columbia culture medium for preparing after high pressure steam sterilization, be cooled to 50-60 DEG C, add 8% horse serum or Sheep Blood, mixing is poured in the culture dish of sterilizing, every ware 7-10ml, culture medium thickness is 1.5mm (sterile working).
(B) experimental bacteria of transferring (being coated with bacterium) gets diluted 10 with microscale sampler
8cFU/ml (1OD
660=10
8cFU/ml) the bacteria suspension 0.1ml of Hp spreads upon suitable culture dish surface equably.Be inverted in 37 DEG C of drying bakers and take out after 15min, object makes agar surface dry, for subsequent use.
(C) paste sample scraps of paper microscale sampler to get 6 μ l testing samples (mass concentration 2mg/ml) and inject on the round filter paper of sterilizing.With aseptic nipper tweezer containing the scraps of paper of sample and the blank scraps of paper of contrast, by sterile working respectively the scraps of paper be close to containing bacterio-agar surface, paste a piece of paper sheet at a certain distance.Often kind of bacterium is cooked 3 wares, and acquired results asks its meansigma methods.
(D) cultivate each plate is placed in micro-aerobic bag, sealing, opens gas generator, then is placed in 37 DEG C of incubators and cultivates 72h.
(E), after surveying antibacterial circle diameter taking-up flat board, the size of antibacterial circle diameter around each scraps of paper is measured respectively.With reference to the result of matched group, the result of testing sample sensitive experiment can be drawn.In triplicate.
II. agar dilution measures MIC
(A) first compound dimethyl sulfoxide (DMSO) solution preparation of test is become the mother solution of 0.5mg/ml by the preparation of Drug plates, then with sterilized water dilution, is finally made into 100.0,80.0,60.0,45.0,40.0,35.0,30.0,25.0,20.0,15.0,10.0, the concentration series of 5.0 and 2.5 μ g/ml, DMSO concentration is in media as well less than 1%.The test compounds solution that 1ml is prepared be incubated 8ml Columbia medium in 50 DEG C, separately add the horse serum that 1ml is incubated in 50 DEG C and fully mix, cast in culture dish cool (in culture dish, the final concentration of chemicals is 10.0,8.0,6.0,4.5,4.0,3.5,3.0,2.5,2.0,1.5,1.0,0.5 and 0.25 μ g/ml, if there is bacteriostasis, then MIC value namely these worthwhile in one).
(B) experimental bacteria of transferring (being coated with bacterium) draws diluted 1 × 10 with microscale sampler
8the bacteria suspension 0.1ml of CFU/ml Hp spreads upon culture dish surface equably, is inverted in 37 DEG C of drying bakers and takes out after 15min, and object makes agar surface dry, for subsequent use.
(C) determine that test dish (contains: 85%N at micro-aerobic bag by MIC
2, 10%CO
2and 5%O
2) in, be incubated 37 DEG C and cultivate 72 hours, observe Hp growing state, contrast with blank group, there is no the sample least concentration of bacteria growing completely for minimum inhibitory concentration (minimal inhibitory concentration, MIC) value.Positive control is ampicillin (Ampicillin).
Experimental result
Experiment in vitro shows, chemicals III has very strong anti Helicobacter pylori activity, and it is 20mm (ATCC43504) that paper disk method shows its antibacterial circle diameter.With agar dilution display, it can suppress the growth of 5 random clinical strains and 1 reference culture (ATCC43504) completely, and minimal inhibitory concentration (MIC) is 2.0 μ g/ml.Make positive control with ampicillin, its Cmin (MIC) suppressed completely 6 strain test bacterium is 1.5 μ g/ml.Chemicals I and 1-ethyl pyrrolidine are without anti Helicobacter pylori activity.
Conclusion: it is active that chemicals III has stronger suppression helicobacter pylori, illustrate for the disease such as the closely-related acute and chronic gastritis of helicobacter pylori, duodenal ulcer, chemicals III is the compound of a great exploitation potential for its.It can be directly used in the treatment of corresponding disease and the preparation of related drugs.Chemicals I and 1-ethyl pyrrolidine, without anti Helicobacter pylori activity, cannot be used for the treatment of corresponding disease and the preparation of related drugs.
Embodiment 8 chemicals III antibacterial activity
Antibacterial activity test is the method adopting concentration dilution, and in triplicate, test pathogen has escherichia coli, fluorescent pseudomonas, Staphylococcus aureus, Bacillus proteus, neogenesis cryptococcus to each mensuration, and bacterial concentration is 10
5individual/mL.Medicine initial concentration is 50.00 μ g/mL (5% dimethyl sulfoxide DMSO), gradient dilution to 0.10 μ g/mL, the bacterium liquid of equivalent volumes and test sample Mixed culture (ultimate density of formation has: 25.00,12.50,6.25,3.13,1.56,0.78,0.39,0.20,0.10 and 0.05 μ g/mL) in 96 orifice plates, antibacterial culturing temperature is respectively 37 DEG C, observe after incubation time 24h, if find, in the disposal hole not having bacterium colony to be formed, that minimum concentration is sample lowest concentration of antimicrobial, i.e. MIC value.Compound III the anti-bacterial result is in table 2.
Table 2 compound III antibacterium MIC value (μ g/mL)
Conclusion: compound III has very strong antibacterial activity, therefore compound III of the present invention is expected to be used to prepare novel anti-bacterial drug.Compound I and 1-ethyl pyrrolidine, without antibacterial activity, can not be used to prepare novel anti-bacterial drug.
Embodiment 9 compound III anti-tubercle bacillus is active
(1) the anti-bacillus calmette-guerin vaccine of solid medium By Dilution compound III (BCG) absolute concentration
Scraping BCG cultures from inclined-plane, join in 3ml Middlebrook7H9 broth bouillon, add a small amount of bead, screw test tube cap, high vibration grinding in vortex oscillator, with standard Maxwell opacity tube (MacFarland No.1) than turbid, be namely made into bacillus calmette-guerin vaccine (BCG) bacteria suspension of 1mg/ml.
Medicine DMSO is made into the stock solution of high concentration, by the tween 80 aseptic ultra-pure water dilution stock solution containing 5% to desired concn, the medicine diluted is joined 4ml Middlebrook7H11 agar culture medium (this culture medium 121 DEG C of high pressure steam sterilizations 15 minutes, be cooled to 50 ~ 55 DEG C) by required dosage, mixing, make drug containing, concentration is respectively 6.0ug/ml, 4.0ug/ml, 3.0ug/ml, 2.0ug/ml, 1.5ug/ml, 1.0ug/ml, the isocyatic slant medium of 0.75ug/ml, 0.5ug/ml.
Be that bacillus calmette-guerin vaccine (BCG) the bacteria suspension inoculating loop of 1mg/ml dips ring of numbers by concentration, be inoculated in containing in the culture medium of each medicine series concentration and blank medium slant respectively, be placed in 37 DEG C to cultivate 4 ~ 8 weeks, observation experiment result, result is as shown in table 3.
In the present embodiment, Middlebrook7H9 broth bouillon used and Middlebrook7H11 agar culture medium are the conventional culture medium that those skilled in the art carry out when tulase is cultivated, and its formula adopts conventional formulation.
(2) solid medium By Dilution compound III Killing Mycobacterium Tuberculosis type strain H37Rv strain absolute concentration
Scraping mycobacterium tuberculosis type strain H37Rv strain culture from inclined-plane, join in 3ml Middlebrook7H9 broth bouillon, add a small amount of bead, screw test tube cap, high vibration grinding in vortex oscillator, with standard Maxwell opacity tube (MacFarland No.1) than turbid, be namely made into the H37Rv strain bacteria suspension of 1mg/ml.
Medicine is made into respectively the stock solution of high concentration with DMSO, by the tween 80 aseptic ultra-pure water dilution stock solution containing 5% to desired concn, the medicine diluted is joined 4ml Middlebrook7H11 agar culture medium (this culture medium 121 DEG C of high pressure steam sterilizations 15 minutes, be cooled to 50 ~ 55 DEG C) by required dosage, mixing, make drug containing, concentration is respectively 6.0ug/ml, 4.0ug/ml, 3.0ug/ml, 2.0ug/ml, 1.5ug/ml, 1.0ug/ml, the isocyatic slant medium of 0.75ug/ml, 0.5ug/ml.
Be that the H37Rv strain bacteria suspension inoculating loop of 1mg/ml dips ring of numbers by concentration, in the culture medium being inoculated in drug containing series concentration respectively and blank medium slant, be placed in 37 DEG C and cultivate 4 ~ 8 weeks, observation experiment result, result is as shown in table 3.
(3) the clinical separation of the solid medium By Dilution compound III Ad tuberculosis MTB of resistance to ISRE strain absolute concentration
The clinical separation of the scraping mycobacterium tuberculosis MTB of resistance to ISRE strain (resistance to isoniazid, streptomycin, rifampicin, the clinical detached dowel of ethambutol mycobacterium tuberculosis) culture from inclined-plane, join in 3ml Middlebrook7H9 broth bouillon, add a small amount of bead, screw test tube cap, high vibration grinding in vortex oscillator, with standard Maxwell opacity tube (MacFarland No.1) than turbid, be namely made into the bacteria suspension of 1mg/ml.
Medicine is made into respectively the stock solution of high concentration with DMSO, by the tween 80 aseptic ultra-pure water dilution stock solution containing 5% to desired concn, the medicine diluted is joined 4ml Middlebrook7H11 agar culture medium (this culture medium 121 DEG C of high pressure steam sterilizations 15 minutes, be cooled to 50 ~ 55 DEG C) by required dosage, mixing, make drug containing, concentration is respectively 6.0ug/ml, 4.0ug/ml, 3.0ug/ml, 2.0ug/ml, 1.5ug/ml, 1.0ug/ml, the isocyatic slant medium of 0.75ug/ml, 0.5ug/ml.
Be that the clinical separation of the mycobacterium tuberculosis MTB of the resistance to ISRE strain bacteria suspension inoculating loop of 1mg/ml dips ring of numbers by concentration, be inoculated in containing in the culture medium of each medicine series concentration and blank medium slant respectively, be placed in 37 DEG C to cultivate 4 ~ 8 weeks, observation experiment result, result is as shown in table 3.
Table 3 solid medium By Dilution compound III anti-tubercle bacillus absolute concentration result
Table 4 solid medium By Dilution Compound I anti-tubercle bacillus absolute concentration result
Table 3 solid medium By Dilution 1-ethyl pyrrolidine anti-tubercle bacillus absolute concentration result
Conclusion: compound III has very strong anti-tubercle bacillus and anti-drug resistance tulase is active, can be used as the lead compound for the treatment of tubercle bacillus affection disease, also can be used for preparation treatment tubercular drugs.Compound I and 1-ethyl pyrrolidine without remarkable anti-tubercle bacillus and anti-drug resistance tulase active, can not as the lead compound for the treatment of tubercle bacillus affection disease, can not for the preparation for the treatment of tubercular drugs.
Claims (9)
1. there is Daphmalenine A derivant and the application of pharmaceutically acceptable salt in antibacterials thereof of structure shown in formula III,
2. a kind of Daphmalenine A derivant and the application of pharmaceutically acceptable salt in antibacterials thereof with structure shown in formula III as claimed in claim 1, is characterized by: described bacterium is antibacterial.
3. a kind of Daphmalenine A derivant and the application of pharmaceutically acceptable salt in antibacterials thereof with structure shown in formula III as claimed in claim 1, is characterized by: described bacterium is fungus.
4. a kind of Daphmalenine A derivant and the application of pharmaceutically acceptable salt in antibacterials thereof with structure shown in formula III as claimed in claim 1, is characterized by: described bacterium is helicobacter pylori.
5. a kind of Daphmalenine A derivant and the application of pharmaceutically acceptable salt in antibacterials thereof with structure shown in formula III as claimed in claim 1, is characterized by: described bacterium is tulase.
6. a kind of Daphmalenine A derivant and the application of pharmaceutically acceptable salt in antibacterials thereof with structure shown in formula III as claimed in claim 3, is characterized by: described fungus is trichophyton, microsporum canis or trichophyton tonsurans.
7. a kind of Daphmalenine A derivant and the application of pharmaceutically acceptable salt in antibacterials thereof with structure shown in formula III as claimed in claim 2, is characterized by: described antibacterial is escherichia coli, fluorescent pseudomonas, Staphylococcus aureus, Bacillus proteus or neogenesis cryptococcus.
8. a kind of Daphmalenine A derivant and the application of pharmaceutically acceptable salt in antibacterials thereof with structure shown in formula III as claimed in claim 5, is characterized by: described tulase is bacillus calmette-guerin vaccine, the H37Rv strain of mycobacterium tuberculosis type strain and substance of medicines-resistant branched tubercle bacillus.
9. a kind of Daphmalenine A derivant and the application of pharmaceutically acceptable salt in anti-and the closely-related acute and chronic gastritis of helicobacter pylori, duodenal ulcer disease medicament thereof with structure shown in formula III as claimed in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510240655.0A CN104887668A (en) | 2015-05-12 | 2015-05-12 | Application of Daphmalenine A derivate in antibacterial agent preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510240655.0A CN104887668A (en) | 2015-05-12 | 2015-05-12 | Application of Daphmalenine A derivate in antibacterial agent preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104887668A true CN104887668A (en) | 2015-09-09 |
Family
ID=54020914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510240655.0A Pending CN104887668A (en) | 2015-05-12 | 2015-05-12 | Application of Daphmalenine A derivate in antibacterial agent preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104887668A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105343086A (en) * | 2015-10-14 | 2016-02-24 | 南京大学 | Composition and application thereof in antibacterial drugs |
| CN105616423A (en) * | 2015-12-29 | 2016-06-01 | 南京大学 | Composition and application of composition to antibacterial medicine |
-
2015
- 2015-05-12 CN CN201510240655.0A patent/CN104887668A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| YU ZHANG等: "Daphmalenines A and B: Two New Alkaloids with Unusual Skeletons from Daphniphyllum himalense", 《EUR. J. ORG. CHEM》 * |
| 李震宇等: "虎皮楠生物碱研究进展", 《有机化学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105343086A (en) * | 2015-10-14 | 2016-02-24 | 南京大学 | Composition and application thereof in antibacterial drugs |
| CN105616423A (en) * | 2015-12-29 | 2016-06-01 | 南京大学 | Composition and application of composition to antibacterial medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104083377B (en) | The application in preparation antibacterials of the dimethylamine derivative of Cleistanone Cleistanone | |
| CN104098643B (en) | Close the diethylamine derivative of flowers and trees ketone Cleistanone, preparation method and its usage | |
| CN104447938B (en) | O-(piperazinyl) ethyl derivative of Cleistanone, preparation method and its usage | |
| CN104188984B (en) | The application in preparation antibacterials of O-(morpholinyl) ethyl derivative of Cleistanone Cleistanone | |
| CN104887668A (en) | Application of Daphmalenine A derivate in antibacterial agent preparation | |
| CN104840470A (en) | Application of cleistanone O-(1H-tetrazole)ethyl derivative in preparation of antibacterial drugs | |
| CN104873509A (en) | Application of O-(diethylamino) ethyl derivative of Daphmalenine A in preparation of antibacterial drug | |
| CN105232513A (en) | Composition and application thereof to antibacterial drugs | |
| CN105287573A (en) | Composition and application thereof to antibacterial medicines | |
| CN105343086A (en) | Composition and application thereof in antibacterial drugs | |
| CN105250287A (en) | Composition and application thereof to antibacterial medicines | |
| CN105395557A (en) | Composition and application thereof to antibacterial medicine | |
| CN105362275A (en) | Composition and application thereof in antibacterial agents | |
| CN105078989A (en) | Composition 77083001030592 and application thereof in antibacterial drugs | |
| CN105287465A (en) | Composition and application thereof to antibacterial medicines | |
| CN105213375A (en) | Compositions and the application in antibacterials thereof | |
| CN105287528A (en) | Composition and application of composition in antibacterial drugs | |
| CN105395556A (en) | Composition and application thereof to antibacterial medicine | |
| CN105193816A (en) | Composition and application thereof in antibacterial drugs | |
| CN104523706A (en) | Application of O-(imidazolyl) ethyl derivative of cleistanone in preparation of antibacterial drug | |
| CN106176726A (en) | The application in antibacterials of the Atropurpuran derivative composition | |
| CN106038524A (en) | Application of composition of derivatives of Artalbic acid in preparation of antibacterial drugs | |
| CN105920014A (en) | Application of composition of tetrahydropyrrolyl and morpholinyl derivatives of Virosaine A in antibacterial medicines | |
| CN106420753A (en) | Application of composition of O-(lignocaine) ethyl derivative and O-(piperazinyl) ethyl derivative of Harrisotone A in antibacterial agents | |
| CN106074518A (en) | The compositions of Artalbic acid derivant is used for preparing antibacterials |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150909 |